Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.68 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127850 | 0.90 | MAPK14 (0.62) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL5998468 | 0.88 | MAPK14 (0.60) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL13670475 | 0.87 | MAPK14 (0.71) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL5820266 | 0.86 | MAPK14 (0.85) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL7144420 | 0.86 | MAPK14 (0.58) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL5997826 | 0.85 | MAPK14 (0.57) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL5903491 | 0.85 | MAPK14 (0.68) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL7162537 | 0.84 | MAPK14 (0.67) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL7139249 | 0.81 | MAPK14 (0.66) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL12856400 | 0.81 | MAPK14 (1.00) | MAPK14MAPK11MAP4K4MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | claimed |
| US-20130337564-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. | 2013-12-19 | — | — | US | claimed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | claimed |
| EP-1028954-B1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO MCNEIL PHARM INC (US) | 2003-07-02 | — | — | EP | claimed |
| EP-1028954-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-23 | — | — | EP | claimed |
| US-5965583-A | ANTIINFLAMMATORY AGENTS IN THE TREATMENT OF DISEASES ASSOCIATED WITH OVERPRODUCTION OF INFLAMMATORY CYTOKINES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-12 | — | — | US | claimed |
| WO-1998047892-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO-MCNEIL CORPORATION, INC. (US) | 1998-10-29 | — | — | WO | claimed |
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20060241150-A1 | P38 kinase inhibitor compositions and methods of using the same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2006-10-26 | — | — | US | disclosed |
| EP-1631145-A2 | P38 KINASE INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005000405-A2 | P38 KINASE INHIBITOR COMPOSITIONS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1028954-B1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO MCNEIL PHARM INC (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1028954-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-5965583-A | ANTIINFLAMMATORY AGENTS IN THE TREATMENT OF DISEASES ASSOCIATED WITH OVERPRODUCTION OF INFLAMMATORY CYTOKINES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1998047892-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO-MCNEIL CORPORATION, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241150-A1 | P38 kinase inhibitor compositions and methods of using the same | MAPK7, MAPK1, MAP3K7 | MAPK14 19/4885MAPK11 54/4885MAP4K4 66/4885 |
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | GSK3B, GSK3A, GSKIP | MAPK14 2384/4885MAPK11 3117/4885MAP4K4 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.